Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells

Cancer Research

Volumn 60, Issue 11, 2000, Pages 2981-2987

  Kawakami, Koji ^a   Leland, Pamela ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; STAT6 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; GENE TARGETING; HEAD CANCER; HUMAN; HUMAN CELL; NECK CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, NORTHERN; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; KINETICS; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-4; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT6 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0034212488     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Correa, A. J., and Burkey, B. B. Current options in management of head and neck cancer patients. Med. Clin. North Am., 83: 235-246, 1999.
2. Landis, S. H., Murray, T., Bolden, S., and Wingo. P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
3. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced squamous cell carcinoma: final report. Cancer (Phila.). 60: 301-311, 1987.
4. Schuller, D. E., Metch, B., Stein, D. W., Mattox, D., and McCracken, J. D. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope, 98: 1205-1211, 1988.
5. Puri, R. K., and Siegel, J. P. Interleukin-4 and cancer therapy. Cancer Invest., II: 473-486, 1993.
6. Puri, R. K. Structure and function of interleukin-4 and its receptor. In: R. Kurzock (ed.), Cytokines: Interleukins and Their Receptors, pp. 143-185. Norwell, MA: Kluwer Academic, 1995.
7. Obiri, N. I., Hillman, G. G., Haas, G. P., Sud, S., and Puri, R. K. Expression of high affinity interleukin-4 receptors on human renal carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest., 91: 88-93, 1993.
8. Obiri, N. I., Siegel, J., Varricchio. F., and Puri, R. K. Expression of high-affinity 1L-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol., 95: 148-155, 1994.
9. Idzerda, R. L., March, C. J., Mosley, B., Lyman, S. D., Bos, T. V., Giempel, S. D., Din, W. S., Grabstein, K. H. Widmer, M. B., Park, L. S., Cosman, D., and Beckmann, M. P. Human interleukin-4 receptor confers biological responsiveness and defines a novel receptor superfamily, J. Exp. Med., 171: 861-873, 1990.
10. Obiri, N. I., Debinski, W., Leonard, W. J., and Puri, R. K. Receptor for interleukin 13: interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15, J. Biol. Chem., 270: 8797-8804, 1995.
11. Murata, T., Obiri, N. I., Debinski, W., and Puri, R. K. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun., 238: 90-94, 1997.
12. Murata, T., Noguchi, P. D., and Puri, R. K. Receptors for interleukin (IL)-4 do not associate with the common γ chain, and IL-4 induces the phosphorylation of Jak2 tyrosine kinase in human colon carcinoma cells. J. Biol. Chem., 270: 30829-30836, 1995.
13. Murata, T., Obiri, N. I., and Puri, R. K. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13 induced signal transduction. Int. J. Cancer. 70: 230-240, 1997.
14. Murata, T., Obiri, N. I., and Puri, R. K. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors. Int. J. Mol. Med., 1: 551-557, 1998.
15. Murata, T., Taguchi, I., and Puri, R. K. Interleukin-13 receptor α′ but not α chain: a functional component of interleukin-4 receptors. Blood, 91: 3884-3891, 1998.
16. Husain, S. R., Kreitman, R. J., Pastan, I., and Puri, R. K. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat. Med., 5: 817-822, 1999.
17. Hoon, D. S. B., Okun, E., Banez, M., Irie, R. F., and Morton, D. L. Interleukin 4 alone and with γ-interferon or tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res., 51: 5687-5693, 1991.
18. Toi, M., Bicknel, R., and Harris, A. L. Inhibition of colon and breast carcinoma growth by interleukin-4. Cancer Res., 52: 275-279, 1992.
19. Morisaki, T., Yuzuki, D. H., Lin, R. T., Foshag. L. J., Morton. D. L., and Hoon, D. S. B. Interleukin-4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin-4. Cancer Res., 52: 6059-6065, 1992.
20. Paul, W. E. Interleukin 4: a prototypic immunoregulatory lymphokine. Blood, 77: 1859-1870, 1991.
21. Gooch, J. L., Lee, A. V., and Yee, D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res., 58: 4199-4205, 1998.
22. Myers, J. N., Yasumura, S., Suminami, Y., Hirabayashi, H., Lin, W-C., Johnson J. T., Lotze, M. T., and Whiteside, T. L. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin. Cancer Res., 2; 127-135, 1996.
23. Puri, R. K., Leland, P., Kreitman, R. J., and Pastan, I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the cytotoxic effect of IL4-Pseudomonas exotoxin chimeric protein. Int. J. Cancer, 58: 574-581, 1994.
24. Puri, R. K., Hoon, D. S., Leland, P., Snoy. P., Rand, R. W., Pastan, I., and Kreitman, R. J. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res., 56: 5631-5637, 1996.
25. Kreitman, R. J., Puri, R. K., and Pastan, I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc. Natl. Acad. Sci. USA, 91: 6889-6893, 1994.
26. Kreitman, R. J., Puri, R. K., and Pastan, I. Increased antitumor activity of circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res., 55: 3357-3363, 1995.
27. c chain in RCC cells does not improve sensitivity. Cell. Immunol., 171: 80-86, 1996.
28. Husain, S. R., Gill, P., Kreitman, R. J., Pastan, I., and Puri, R. K. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol. Med., 3: 327-338, 1997.
29. Husain, S. R., Behari, N., Kreitman, R. J., and Puri, R. K. Complete regression of established human glioblastoma xenograft by interleukin-4 therapy. Cancer Res., 58: 3649-3653, 1998.
30. Mehrotra, R., Varricchio, F., Husain, S. R., and Puri, R. K. Head and neck cancers, but not benign lesions, express interleukin-4 receptors in situ. Oncol. Rep., 5: 45-48, 1998.
31. Debinski, W., Obiri, N. I., Pastan, I., and Puri, R. K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem., 270: 16775-16780, 1995.
32. Oshima, Y., Joshi, B. H., and Puri, R. K. Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution. J. Biol. Chem., in press, 2000.
33. Cardinali M., Pietraszkiewicz, H., Ensley, J. F., and Robbins, K. C. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer, 61: 98-103, 1995.
34. Kawakami, K., Tsukuda, M., Mizuno, H., Nishimura, G., Ishii, A., and Hamajima, K. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res., 19: 3927-3932, 1999.
35. Munson, P. J., and Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem., 107: 220-239, 1980.
36. Ohmori, Y., Smith, M. F., Jr., and Hamilton, T. A. IL-4-induced expression of the IL-I receptor antagonist gene is mediated by Stat6. J. Immunol., 157: 2058-2065, 1996.
37. Puri, R. K., Ogata, M., Leland, P., Feldman, G. M., and Pastan, I. Expression of high affinity IL4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between IL-4 and Pseudomonas exotoxin. Cancer Res., 51: 3011-3017, 1991.
38. Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., and Paul, W. E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol., 17: 701-738, 1999.
39. Keppler-Hafkemeyer, A., Brinkmann, U., and Pastan, I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry, 37: 16934-16942, 1998.
40. Leland, P., Taguchi, J., Husain, S. R., Kreitman, R. J., Pastan, I., and Puri, R. K. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol. Med., in press, 2000.